Literature DB >> 19559818

Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm.

David Y Graham.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19559818      PMCID： PMC2838428          DOI： 10.1016/j.cgh.2009.06.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  29 in total

Review 1.  Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies.

Authors:  Sonia Hernández-Díaz; Luis Alberto García Rodríguez
Journal:  J Clin Epidemiol       Date:  2002-02       Impact factor: 6.437

2.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Authors:  David Y Graham; Naurang M Agrawal; Donald R Campbell; Marian M Haber; Cyndy Collis; Nancy L Lukasik; Bidan Huang
Journal:  Arch Intern Med       Date:  2002-01-28

3.  Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.

Authors:  David Y Graham
Journal:  Helicobacter       Date:  2002-02       Impact factor: 5.753

4.  A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents.

Authors:  R E Pemberton; L J Strand
Journal:  Dig Dis Sci       Date:  1979-01       Impact factor: 3.199

5.  Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs.

Authors:  F K Chan; J J Sung; J Y Ching; J C Wu; Y T Lee; W K Leung; Y Hui; L Y Chan; A C Lai; S C Chung
Journal:  Aliment Pharmacol Ther       Date:  2001-01       Impact factor: 8.171

6.  Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

Authors:  Francis K L Chan; Lawrence C T Hung; Bing Y Suen; Vincent W S Wong; Aric J Hui; Justin C Y Wu; Wai K Leung; Yuk T Lee; Ka F To; S C Sydney Chung; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

7.  Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents.

Authors:  F L Lanza
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

8.  Gastric adaptation occurs with aspirin administration in man.

Authors:  D Y Graham; J L Smith; S M Dobbs
Journal:  Dig Dis Sci       Date:  1983-01       Impact factor: 3.199

Review 9.  Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm.

Authors:  Andrew Moore; Ingvar Bjarnason; Byron Cryer; Luis Garcia-Rodriguez; Larry Goldkind; Angel Lanas; Lee Simon
Journal:  Clin Gastroenterol Hepatol       Date:  2009-04-09       Impact factor: 11.382

10.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Authors:  Francis K L Chan; Lawrence C T Hung; Bing Y Suen; Justin C Y Wu; Kenneth C Lee; Vincent K S Leung; Aric J Hui; Ka F To; Wai K Leung; Vincent W S Wong; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245
View more
  9 in total

Review 1.  Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.

Authors:  Emma D Deeks
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

2.  Assessing the Need for Proton Pump Inhibitors for Patients Using Long-Term Nonsteroidal Anti-inflammatory Drugs without a History of Ulcers.

Authors:  Kevin Kwok; Aaron Tejani
Journal:  Can J Hosp Pharm       Date:  2020-06-01

Review 3.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

4.  Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Authors:  David Y Graham; Nicholas P Jewell; Francis K L Chan
Journal:  Am J Med Sci       Date:  2011-11       Impact factor: 2.378

5.  Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.

Authors:  Ying He; Esther W Chan; Kenneth K C Man; Wallis C Y Lau; Wai K Leung; Lai M Ho; Ian C K Wong
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

6.  Toward More GI-Friendly Anti-Inflammatory Medications.

Authors:  John L Wallace; Gilberto de Nucci; Oksana Sulaieva
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12

7.  Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.

Authors:  Jin-Qiu Yuan; Chen Mao; Samuel Yeung-Shan Wong; Zu-Yao Yang; Xiao-Hong Fu; Xiao-Yu Dai; Jin-Ling Tang
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 8.  Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.

Authors:  R Andrew Moore
Journal:  Arthritis Res Ther       Date:  2013-07-24       Impact factor: 5.156

9.  Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study.

Authors:  Naomi Uemura; Kentaro Sugano; Hideyuki Hiraishi; Kazuyuki Shimada; Shinya Goto; Shinichiro Uchiyama; Yasushi Okada; Hideki Origasa; Yasuo Ikeda
Journal:  J Gastroenterol       Date:  2013-06-12       Impact factor: 7.527
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.